Spanish multidisciplinary consensus on the prevention of respiratory syncytial virus infection in children;Consenso multidisciplinar español sobre la profilaxis de la infección respiratoria pediátrica por virus respiratorio sincitial

Anales de Pediatria

Volumn 69, Issue 1, 2008, Pages 63-71

  Figueras Aloy, J ^a,b   Lopez Sastre J ^a   Medrano Lopez C ^a   Bermudez Canete Fernandez R ^a   Fernandez Pineda L ^a   Bonillo Perales, A ^a   Perez Yarza E G ^a   Diaz De Heredia C ^a   Sanchez De Toledo J ^a  

^a Sociedad Española de Neonatología ^*

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Consensus; Paediatrics; Prophylaxis; RSV

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD CARE; CONSENSUS DEVELOPMENT; HEALTH SURVEY; HUMAN; HYGIENE; IMMUNOPROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPAIN; VIRUS INFECTION;

EID: 46849116645     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13124223     Document Type: Article

References (52)

1. Dalkey N, Brown B, Cochran S. The Delphi Method, III: Use of Self Ratings to Improve Group Estimates. Santa Monica, Calif: Rand Corp; November 1969. Publication RM-6115-PR.
2. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118:1774-93.
3. Behrendt CE, Decker MK, Burch DJ, Watson PH. International RSV Study Group. International variation in the management of infants hospitalized with respiratory syncytial virus. Eur J Pediatr. 1998;157:215-20.
4. Bloemeres BLP, Van Furth AM, Weijerman ME, Gemke RJB, Broers CJM, Van den Ende K, et al. Down Syndrome: A novel risk factor for respiratory syncytial virus bronchiolitis. A prospective birth-cohort study. Pediatrics. 2007;120:e1076-81.
5. Bonillo Perales A, Díez-Delgado Rubio J, Ortega Montes A, Infante Márquez P, Jiménez Liria MR, Batlles Garrido J, et al. Antecedentes perinatales y hospitalización por bronquiolitis. Comparación con el Impact-RSV Study Group. An Esp Pediatr. 2000;53:527-32.
6. Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865-70.
7. Bustos Lozano G, De la Cruz Bértolo J, Farfán Sedano FJ. Recomendaciones de inmunoprofilaxis del virus respiratorio sincitial con palivizumab. Efectividad de medicamentos en Neonatología. Comunidad de Madrid: Dirección General de Farmacia y Productos Sanitarios, Consejería de Sanidad y Consumo; febrero de 2004, no.1.
8. Carbonell-Estrany X, Quero J; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001;20:874-9.
9. Chávez-Bueno S, Mejías A, Welliver RC. Respiratory syncytial virus bronchiolitis. Current and future strategies for treatment and prophylaxis. Treat Respir Med. 2006;5:483-94.
10. Chiroli S, Macagno F, Lucioni C. Cost-efficacy analysis of palivizumab in the prevention of Respiratory Syncytial Virus infections in young children wiyh hemodynamically significant congenital heart disease. Ital J Pediatr. 2005;31:188-94.
11. Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcase E, Zerr DM. Variation in inpatient diagnostic testing and management of bronchiolitis. Pediatrics. 2005;115:878-83.
12. Cilla G, Sarasua A, Montes M, Arostegui N, Vicente D, Pérez-Yarza E, Pérez-Trallero E. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect. 2006;134:506-13.
13. Cohen SA, Zanni R, Cohen A, Harrington M, Vanveldhuisen P, Boron ML; for the Palivizumab Outcomes Registry Group. Palivizumab Use in Subjects with Congenital Heart Disease: Results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Cardiol. 2007 Oct 10; doi:10.1007/s00246-007-9039-5.
14. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low Incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child. 2004;89:961-5.
15. ElHassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediar Adolesc Med. 2006;160:1070-6.
16. El Saleeyby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus Disease in Children with cancer: The importante of lymphopenia and young age. Pediatrics. 2008;121:235-43.
17. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al, for the Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significat congenital heart disease. J Pediatr. 2003;143:532-40.
18. Ficha técnica de Synagis-Abbott.
19. Figueras Aloy J, Carbonell-Estrany X, Quero J, para el Iris Study Group. Estudio de casos y controles de los factores de riesgo relacionados con la infección por el virus respiratorio sincitial que precisa hospitalización en niños prematuros de 33-35 semanas de edad gestacional en España. Pediatr Infect Dis J. 2004;23:815-20.
20. Figueras Aloy J, Quero J, y el Comité de Estándares de la Sociedad Española de Neonatología. Recomendaciones para la prevención de la infección por virus respiratorio sincitial. An Pediatr (Barc). 2005;63:357-62.
21. Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB; Burgundy Perinatal Network. Severe respiratory syncytial virus bronchiolitis: Epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 2004;23:1081-5.
22. Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, et al. Palivizumab propylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population. Pediatr Infect Dis J. 2004;23:27-31.
23. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104:419-27.
24. Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs. Incidence of respiratory syncytial virus related hospitaliztions in high-risk children. Pediatr Pulmonol. 2002;34:181-8.
25. Lacaze-Masmonteil T, Truffert P, Pinquier D, Daoud P, Goldfarb G, Vicaut E, et al. Lower respiratory tract illness and RSV prophylaxis in veri premature infants. Arch Dis Child. 2004;89:562-7.
26. Law BJ, Langley JM, Allen U, Paes B, Lee DSC, Mitchell I, et al. The Pediatric Investigators Collaborative Network on Infections in Canada Study of predictors of hospitalization for respiratory syncitial virus. Pediatr Infect Dis. 2004;23:806-14.
27. Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, et al. La eficencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España. An Pediatr (Barc). 2006;65:316-24.
28. Medrano C, García-Guereta L, Grueso J, Insa B, Ballesteros F, Casaldaliga J, et al; CIVIC Study Group from the Spanish Society of Pediatric Cardiology and Congenital Heart Disease. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: The CIVIC Epidemiologic Study. Cardiol Young. 2007;17:360-71.
29. Nakazawa M, Saji T, Ichida F, Oyama K, Harada K, Kususda S. Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr Int. 2006;48:190-3.
30. Nuijten MJC, Wittenberg W, Lemeier M. Cost effectiveness of pavilizumab for respiratory syncytial virus prophylaxis in high-risk children. Pharmacoeconomics. 2007;25:55-71.
31. Oh PI, Lanctĵt KL, Yoon A, Lee DS, Paes BA, Simmons BS, et al; Composs Investigators. Palivizumab prophylaxis for respiratory syncytial virus in Canada: Utilization and outcomes. Pediatr Infect Dis J. 2002;21:512-8.
32. Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35:484-9.
33. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, and The Iris Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22:823-7.
34. Pérez-Yarza EG, Moreno A, Lázaro P, Mejías A, Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma: A systematic review of the literature. Pediatr Infect Dis J. 2007;26:733-9.
35. Prais D, Schonfeld T, Amir J. Admission to the Intensive Care Unit for respiratory syncytial virus bronchiolitis: A national survey before palivizumab use. Pediatrics. 2003;112:548-52.
36. Respiratory Syncytial Virus. Red Book Online. 2003;1:523. [Section 3. Summaries of Infections Diseases].
37. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143:S150-S156.
38. Scottish Intercollegiate Guidelines Network. Bronchiolitis in children: A national clinical guideline. 2007. Disponible en: http://www.sing.ac.uk/pdf/ sign91.pdf
39. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501-7.
40. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt D, Sigurbergsson F, et al Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171:137-41.
41. Smyth RL, Openshaw PJM. Bronchiolitis. Lancet. 2006;368:312-22.
42. Stein RT, Halonen M, Sherrill D, Taussig LM, Morgan WJ, Wright AL, et al. Virus respiratorio sincitial en la fase inicial de la vida y riesgo de sibilancias y alergia hasta los 13 años. Lancet. 1999;354:541-5.
43. Suárez Cabrera P, Malo Concepción P, Maroto E, Santos de Soto J. Recomendaciones para la prevención de la infección por virus respiratorio sincitial en pacientes con cardiopatía congénita. SECP. Disponible en: www.secardioped.org/pdfs/ profilaxis_virus_vrs.pdf
44. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-7.
45. Tulloh R, Marsh M, Blackburn M, Casey F, Lenney W, Weller P, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young. 2003;13:420-3.
46. Wang EEL, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection. Cochrane Database Syst Rev. 1999;(3):CD001725.
47. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program. Pediatrics. 2004;114:1612-9.
48. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med. 1997;157:1531-6.
49. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Results of a US Consensus Panel of Experts. Arch Intern Med. 2003;163:2716-24.
50. Almansa C, Rey E, Bolaños E, Palma M, Álvarez A, Díaz-Rubio M. Opinión de los médicos españoles sobre el síndrome de intestino irritable: Resultados de un estudio utilizando el método Delphi. Rev Esp Enferm Dig. 2007;99:210-7.
51. Dago A, Arcos P, Álvarez de Toledo F, Baena MI, Martínez J, Gorostiza I. Indicadores de riesgo de morbilidad prevenible causada por medicamentos. Gac Sanit. 2007;21:29-36.
52. Holey EA, Feeley JL, Dixon J, Whittaker VJ. An exploration of the use of simple statistics to measure consensus and stability in Delphi studies. BMC Med Res Methodol. 2007;7:52.